Status:
COMPLETED
Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 in Healthy Volunteers
Lead Sponsor:
AstraZeneca
Conditions:
Healthy Volunteers
Eligibility:
All Genders
20-55 years
Phase:
PHASE1
Brief Summary
The primary aim of this study is to investigate the safety and tolerability of AZD2423 single doses in healthy volunteers.
Eligibility Criteria
Inclusion
- Provision of signed and dated, written informed consent prior to any study specific procedures
- Have a body mass index (BMI) between ≥18 and ≤30 kg/m2, as calculated by the investigator, and weigh at least 50 kg and no more than 100 kg
- Healthy male and non-fertile female volunteers with suitable veins for cannulation or repeated venipuncture
Exclusion
- History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study,or influence the results or the subject's ability to participate in the study
- History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
- Any clinically significant illness/infection or medical/surgical procedure or trauma,as judged by the Principal Investigator, within 3 months of the first administration of investigational product
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00940212
Start Date
July 1 2009
End Date
November 1 2009
Last Update
December 10 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Berlin, Germany